Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 11/20 | 0.59 |
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | CLK1 | P49759 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30270516 | 0.84 | LMNA (1.00) | POLBSMN1; SMN2LMNAALDH1A1ALOX15 | |
| SCHEMBL5912909 | 0.84 | LMNA (0.78) | POLBSMN1; SMN2LMNAALDH1A1ALOX15 | |
| SCHEMBL2636675 | 0.84 | LMNA (1.00) | POLBSMN1; SMN2LMNAALDH1A1ALOX15 | |
| SCHEMBL18618415 | 0.83 | LMNA (0.72) | POLBSMN1; SMN2LMNAALDH1A1ALOX15 | |
| SCHEMBL24124207 | 0.83 | LMNA (0.76) | POLBSMN1; SMN2LMNAALDH1A1ALOX15 | |
| SCHEMBL30270575 | 0.83 | LMNA (0.76) | POLBSMN1; SMN2LMNAALDH1A1ALOX15 | |
| SCHEMBL8551997 | 0.83 | POLB (0.70) | POLBSMN1; SMN2LMNAALDH1A1ALOX15 | |
| SCHEMBL7488353 | 0.82 | POLB (0.70) | POLBSMN1; SMN2LMNAALDH1A1ALOX15 | |
| SCHEMBL25920701 | 0.81 | POLB (0.67) | POLBSMN1; SMN2LMNAALDH1A1ALOX15 | |
| SCHEMBL10651410 | 0.80 | LMNA (0.71) | POLBSMN1; SMN2LMNAALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-11-03 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | POLB 3341/4885SMN1; SMN2 3613/4885LMNA 4160/4885 |
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | DRD4, DRD2, DRD3 | POLB 3812/4885SMN1; SMN2 2784/4885LMNA 4883/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | POLB 3244/4885SMN1; SMN2 3709/4885LMNA 3860/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | POLB 3341/4885SMN1; SMN2 3613/4885LMNA 4160/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | POLB 3341/4885SMN1; SMN2 3613/4885LMNA 4160/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | POLB 3244/4885SMN1; SMN2 3709/4885LMNA 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.